1660A Old Pecos Trail
Avisa is a clinical stage company that is developing a novel technology that rapidly detects a variety of respiratory pathogens within minutes after the patient inhales its proprietary drug substrate, AV-U13. BreathTest™ is a rapid 10-minute test that screens and detects respiratory infections including pneumonia, tuberculosis, and pulmonary diseases such as COPD and cystic fibrosis with the speed and sensitivity that can also facilitate the monitoring of antibiotic therapy. The AVISAR SPEC™ laser spectrometer, under development by Avisa, incorporates major design advancements that have resulted in a portable, laptop-size detection device that will have enormous utility in point-of-care settings—from rural health clinics in the developing world to modern medical clinics and hospitals. For more information, please visit the Company’s website at www.avisapharma.com.
Co-Founder and CEO: David S. Joseph
CMO: Elizabeth A. Perkett
Chief Science Advisor: Graham S. Timmins, PH.D.
Senior Vice President, Product Development: David Karshmer
Vice President, Product Management: John Maynard
Vice President, Finance: Matt Culler